Forecasting the value of biopharmaceutical and Med Tech assets often begins with the US market due to its size and significance. However, successfully transitioning these forecasts to European markets or beginning with a Europe-first strategy requires careful consideration and expertise, often leading to redefinition of forecast structures and assumptions. Drawing on examples from our extensive forecasting experience, we outline a comprehensive checklist that highlights the critical differences between the US and European markets and forecasts.